Helicon Group Limited

ASX:HCG ISIN:AU000000HCG1

May 26, 2012

OVERVIEW | NEWS | MULTIMEDIA | RESEARCH

Helicon Group Limited Company Summary

Helicon is listed on the Australian Securities Exchange. The Company's business is to identify and exploit niche market opportunities in the biomedical markets of North Asia, specifically China and to participate in the significant growth that has been projected for these markets over the next 25 years.

Helicon looks for "Special Situations" for advanced Western biopharmaceutical products that are not available in China or other North Asian Markets or where there are market needs that are not being adequately provided for.

Helicon's product partners are likely to be innovative small to medium sized pharmaceutical and healthcare enterprises focused largely on western markets.

Helicon seeks exclusive licenses for the designated markets and utilises a low cost operating overhead base in combination with established channel partners for product registration, distribution, marketing, and sales.

ANNUAL REPORT

COMPANY DATA

	Headquarters	Suite 3, 257 York Street

		SUBIACO WA 6008

		Australia

	Telephone	+61-8-9388-3683

	Fax	+61-8-9382-1766

	Principal Sector	Health & Pharm

	Principal Industry	Biotechnology

	Homepage	www.helicongroup.com.au

Key Developments: Helicon Group Limited

	Asian Activities Report for October 18, 2011: Algae. Tec Limited (ASX:AEB) to Build Algae Demonstration Plant in Sydney for Alternative Fuel Solutions OCT 18, 2011 13:03 - Article Views: 1,183 Asian Activities Report for October 18, 2011 includes: Algae. Tec Limited (ASX:AEB) has received regulatory approvals for the development of an algae demonstration plant in the south of Sydney; Helicon Group Limited (ASX:HCG) today announces the execution of a definitive agreement to acquire Aspen Medisys; Alkane Resources Limited (ASX:ALK) has signed an agreement with the NSW Government to receive financial assistance for the infrastructure development of the Tomingley Gold Project in the Central West of NSW; Transerv Energy Limited (ASX:TSV) has completed the initial 10-day test of the Upper Zone at the Warro-4 onshore well in Western Australia; Augur Resources Limited (ASX:AUK) reports extensive gold and copper results from the Randu Kuning prospect, Wonogiri project in Central Java.

	Helicon Group Limited (ASX:HCG) Restructure Set To Reduce Operating Costs By Up To 50% NOV 11, 2008 13:08 - Article Views: 2,120 HELICON GROUP LIMITED (ASX:HCG) announced today that it has implemented a restructuring and cost reduction program in response to the ongoing delays by the Chinese regulatory authority, the State Food and Drug Administration (SFDA), to grant regulatory approvals across the board and an anticipated slow down in economic activity in China.

	Chinese SFDA Approves Helicon's (ASX:HCG) ReCell(R) Concept And Kit JULY 21, 2008 17:12 - Article Views: 2,752 Helicon Group Limited (ASX:HCG) is pleased to announce that earlier this month the Chinese State Food and Drug Administration (SFDA) granted approval for the skin regeneration concept and device, ReCell(R), for sale in China.

	Helicon Group Limited (ASX:HCG) Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R) JULY 3, 2008 12:32 - Article Views: 4,110 HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

	Helicon Group (ASX:HCG) Announce 3rd Party Equity Research Report by Money Cat Consulting JUNE 5, 2008 17:03 - Article Views: 2,307 Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.

	Helicon Group Limited (ASX:HCG) Present The Company Profile and The China Opportunity MAY 21, 2008 10:04 - Article Views: 4,242 Helicon Group Limited (ASX: HCG) is a pharmaceutical and healthcare company with an innovative strategy, listed on the Australian Securities Exchange. Its business is to identify and exploit niche market opportunities in the specialty pharmaceutical and healthcare markets of China and North Asia and to participate in the significant growth that has been projected for those markets over the next 20 years.

	Helicon Group Limited (ASX:HCG) Secures Exclusive China Rights For Collatamp G, An Innovative Drug Release Surgical Implant MAY 12, 2008 14:48 - Article Views: 2,892 HELICON GROUP LIMITED (ASX: HCG) announced today that it had acquired the exclusive licensing rights from EUSA Pharma to Collatamp(R) G for the Chinese market.

	Helicon Group Limited (ASX: HCG) Intensifies Efforts To Extend Product Portfolio With Swiss Based Executive Appointment JAN 31, 2008 10:04 - Article Views: 1,652 HELICON GROUP LIMITED (ASX: HCG) is pleased to announce the appointment of Anita Wehrli to the position of Business Development Manager based in Switzerland.

	Helicon Group Limited (ASX:HCG) Appoints Aleksandra Gajda To Stakeholder Relations Manager JAN 24, 2008 14:19 - Article Views: 1,912 HELICON GROUP LIMITED (ASX: HCG) today announced the appointment of Aleksandra Gajda to the position of Stakeholder Relations Manager.

	Helicon Group (ASX:HCG) Shareholder Update - Jewim Pharmaceuticals China JAN 14, 2008 14:07 - Article Views: 2,237 With the regulatory process well underway in China, Helicon (ASX: HCG) has put the ReCell(R) pre-marketing program into gear with a number of activities over the last few months.